Sangamo Therapeutics Inc (NASDAQ:SGMO)
| 0.4894 Delayed Data As of Dec 08 |  +0.0319 / +6.97%Today’s Change | 0.29 Today|||52-Week Range 3.76 | -84.41% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $81.1M |
Company Description
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
Contact Information
Sangamo Therapeutics, Inc. 7000 Marina Boulevard Brisbane California 94005 |
Employees
Shareholders
| Mutual fund holders | 29.45% |
| Other institutional | 28.72% |
| Individual stakeholders | 14.59% |
Top Executives
| Alexander D. Macrae | President, Chief Executive Officer & Director |
| Mark D. McClung | Chief Operating Officer & Executive Vice President |
| Prathyusha Durabaibu | Chief Financial & Accounting Officer, Senior VP |
| Gregory Davis | Head-Technology |
| Lisa Rojkjaer | Chief Medical Officer |
